Yunshu Zhang

Yunshu Zhang


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2022 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
MWMin Wen
Min Wen
ZDZhen Dong
Zhen Dong
LZLili Zhang
Lili Zhang
BLBing Li
Bing Li
YZYunshu Zhang
Yunshu Zhang
KLKeqing LI Li
Keqing LI Li
Background: Eye movement is critical for obtaining precise visual information and providing sensorimotor processes and advanced cognitive functions to the brain behavioral indicator. Methods: In this article, we present a narrative review of the eye-movement paradigms (such as fixation, smooth pursuit eye movements, and memory-guided saccade tasks) in major depression. Results: Characteristics of eye movement are considered to reflect several aspects of cognitive deficits regarded as an aid to diagnosis. Findings regarding depressive disorders showed differences from the healthy population in paradigms, the characteristics of eye movement may reflect cognitive deficits in depression. Neuroimaging studies have demonstrated the effectiveness of different eye movement paradigms for MDD screening. Conclusion: Depression can be distinguished from other mental illnesses based on eye movements. Eye movement reflects cognitive deficits that can help diagnose depression, and it can make the entire diagnostic process more accurate.

21 May 2024 in EBioMedicine
Verified
Journal Article
Open access
YLYundan Liao
Yundan Liao
YSYutao Sun
Yutao Sun
JGJing Guo
Jing Guo
ZKZhewei Kang
Zhewei Kang
YSYaoyao Sun
Yaoyao Sun
WYWeihua Yue
Weihua Yue
Understanding the impact of CYP2D6 metabolism on paroxetine, a widely used antidepressant, is essential for precision dosing. We conducted an 8-week, multi-center, single-drug, 2-week wash period prospective cohort study in 921 Chinese Han patients with depressive or anxiety disorders (ChiCTR2000038462). We performed CYP2D6 genotyping (single nucleotide variant and copy number variant) to derive the CYP2D6 activity score and evaluated paroxetine treatment outcomes including steady-state concentration, treatment efficacy, and adverse reaction. CYP2D6 metabolizer status was categorized into poor metabolizers (PMs), intermediate metabolizers (IMs), extensive metabolizers (EMs), and ultrarapid metabolizers (UMs). The influence of CYP2D6 metabolic phenotype on paroxetine treatment outcomes was examined using multiple regression analysis and cross-ethnic meta-analysis. The therapeutic reference range of paroxetine was estimated by receiver operating characteristic (ROC) analyses. After adjusting for demographic factors, the steady-state concentrations of paroxetine in PMs, IMs, and UMs were 2.50, 1.12, and 0.39 times that of EMs, with PM and UM effects being statistically significant (multiple linear regression, P = 0.03 and P = 0.04). Sex and ethnicity influenced the comparison between IMs and EMs. Moreover, poor efficacy of paroxetine was associated with UM, and a higher risk of developing adverse reactions was associated with lower CYP2D6 activity score. Lastly, cross-ethnic meta-analysis suggested dose adjustments for PMs, IMs, EMs, and UMs in the East Asian population to be 35%, 40%, 143%, and 241% of the manufacturer's recommended dose, and 62%, 68%, 131%, and 159% in the non-East Asian population. Our findings advocate for precision dosing based on the CYP2D6 metabolic phenotype, with sex and ethnicity being crucial considerations in this approach. National Natural Science Foundation of China; Academy of Medical Sciences Research Unit.

1 January 2022 in Journal of Affective Disorders
Verified
Journal Article
Closed access
LSLong Sun
Long Sun
KLKeqing Li
Keqing Li
YZYunshu Zhang
Yunshu Zhang
LZLili Zhang
Lili Zhang

24 June 2022 in Frontiers in Psychiatry
Verified
Journal Article
Open access
LSLong Sun
Long Sun
KLKeqing Li
Keqing Li
LZLili Zhang
Lili Zhang
YZYunshu Zhang
Yunshu Zhang
Objective: The age differences in the association between screen time and sleep problems have been implied in many studies, and this study aims to distinguish the associations between evening screen time and sleep quality among different age groups.Methods: This is a population-based, cross-sectional study among community residents aged ≥18 years in China. A total of 21,376 valid questionnaires were analyzed. Sleep quality was measured by the Pittsburgh Sleep Quality Index. Averaged evening screen time (AEST), sociodemographic information, and health-related behaviors were also evaluated in this study.Results: In the 18-to-34-year age group, compared with people without AEST, ≤1 h/day (β = 0.34, p < 0.05) and >3 h/day (β = 1.05, p < 0.001) of AEST were significantly associated with poor sleep quality, and a reverse S-shaped relationship for this association was shown. In the 35-to-49-year and 50-to-64-year age groups, ≤1 h/day (β = 0.43 and 0.36, both p < 0.001), ≤2 h/day (β = 0.43 and 0.31, p < 0.001 and p < 0.01), ≤3 h/day (β = 0.62 and 0.61, both p < 0.001), and >3 h/day (β = 1.55 and 1.88, both p < 0.001) of AEST were positively associated with poor sleep quality. In the 65-year-and-older age group, a J-shaped relationship was found, and ≤3 h/day (β = 0.82, p < 0.001) and >3 h/day (β = 1.84, p < 0.001) of AEST were associated with poor sleep quality.Conclusion: Associations between AEST and sleep quality among different age groups are different. In the 18-to-34-year and 65-year-and-older age groups, acceptable AEST is not related to sleep quality. In the 35-to-49-year and 50-to-64-year age groups, AEST was harmful to sleep quality.

4 August 2022 in Journal of Affective Disorders
Verified
Journal Article
Closed access
JYJianli Yang
Jianli Yang
JFJiaqi Fan
Jiaqi Fan
ACAobo Cheng
Aobo Cheng
WZWuji Zhao
Wuji Zhao
DWDanting Wu
Danting Wu
XLXiuling Liu
Xiuling Liu

17 August 2022 in BMJ Open
Verified
Journal Article
Open access
PDF file
LSLong Sun
Long Sun
KLKeqing Li
Keqing Li
YZYunshu Zhang
Yunshu Zhang
LZLili Zhang
Lili Zhang
Objective This study investigated the prevalence of sleep-related healthcare use and the factors associated with it among adults with different insomnia symptoms. Design and setting This was a population-based study with a cross-sectional design conducted in Hebei province, China. Participants Participants were community residents aged 18 years and above; a total of 21 376 valid questionnaires were analysed. Primary and secondary outcome measures The Athens Insomnia Scale (AIS) was used to evaluate participants’ insomnia symptoms. Variables such as sleep-related healthcare use, chronic disease, living alone and sociodemographics were assessed for all the participants. Results Among adults with any insomnia symptoms, only 2.1% used sleep-related healthcare in the past year. Even for adults with insomnia, the prevalence of sleep-related healthcare use was only 6.2%. Furthermore, the prevalence rates of sleep-related healthcare use among adults with sleep induction, night awakenings, earlier awakening, sleep duration, sleep quality, daytime well-being, daytime functioning, and daytime sleepiness were 3.1%, 2.9%, 3.6%, 3.4%, 3.9%, 4.9%, 4.6% and 2.8%, respectively. The following factors were associated with sleep-related healthcare use among adults with insomnia: male (adjusted OR (aOR)=0.52, p<0.01), younger age (aOR=1.02, p<0.01), rural region (aOR=0.45, p<0.001) and AIS score (aOR=1.23, p<0.001). The same factors were also associated with sleep-related healthcare use among adults with insomnia symptoms. Conclusions The prevalence of sleep-related healthcare use among adults with insomnia symptoms is very low. Young men from rural areas with insomnia symptoms tend not to use healthcare. As such, it is necessary to form policies and strategies to promote sleep-related healthcare use among rural young men with insomnia symptoms.